Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > Genzyme Presents Second Phase III Study of Once-daily Oral Aubagio

FDAnews Drug Daily Bulletin

Oct. 15, 2012 | Vol. 9 No. 202

Genzyme Presents Second Phase III Study of Once-daily Oral Aubagio

Genzyme announced that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Yahoo! Finanace

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Full Issue Experts Spar Over FDA Meeting To Re-Evaluate GSK’s Avandia Shionogi Gets Untitled Letter After Refusing To Conduct Postmarketing Study J&J Eyes Growth Spurt With 10 New Product Launches Planned by 2017

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.